Last reviewed · How we verify
High hyal Plus inj.
High hyal Plus is a hyaluronic acid-based injectable that provides viscoelastic supplementation and tissue hydration for joint or dermatological applications.
High hyal Plus is a hyaluronic acid-based injectable that provides viscoelastic supplementation and tissue hydration for joint or dermatological applications. Used for Osteoarthritis (likely knee or other joints), Dermatological applications (skin hydration/rejuvenation).
At a glance
| Generic name | High hyal Plus inj. |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Drug class | Hyaluronic acid derivative |
| Target | Hyaluronic acid receptors (CD44, RHAMM) |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Hyaluronic acid is a naturally occurring polysaccharide that acts as a lubricant and shock absorber in joints and connective tissues. The 'Plus' formulation likely indicates an enhanced or cross-linked version designed to improve retention time and efficacy. This mechanism supports tissue hydration, reduces friction, and may promote healing in damaged or degenerative tissues.
Approved indications
- Osteoarthritis (likely knee or other joints)
- Dermatological applications (skin hydration/rejuvenation)
Common side effects
- Injection site pain or swelling
- Transient local inflammation
- Allergic reaction
Key clinical trials
- Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Humia Inj. in Patients With Symptomatic Osteoarthritis of the Knee (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High hyal Plus inj. CI brief — competitive landscape report
- High hyal Plus inj. updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI